Ladenburg analyst Jeffrey Cohen upgraded Artivion (AORT) to Buy from Neutral with a $42 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AORT:
- Artivion’s PMA for Nexus Aortic Arch System approved by the FDA
- Artivion’s New Chord-X Mitral Valve Study Sets Stage for Long-Term Value
- Artivion Earnings Call Highlights Growth, Margin Momentum
- Artivion price target lowered to $48 from $51 at Canaccord
- Artivion reports Q4 non-GAAP EPS 17c, consensus 18c